OTC:EMED

Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations

Retrieved on: 
Tuesday, March 14, 2023
PEMF, PNS, FSA, Portal, VNS, Pain, Low-level laser therapy, News, D, EMS, Wellness, CES, Defence Bioengineering and Electromedical Laboratory, Video game, Q2

Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.

Key Points: 
  • Preliminary revenue for the twelve months ended Dec 31 was approximately $1.15 million, which represents a total increase in sales of 26.7% on a year-over-year basis.
  • During the three months ended Dec 31, preliminary revenue increased 79% on a quarterly year-over-year basis and 51% on a sequential quarterly basis.
  • We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance.
  • And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."

Sika Health and Electromedical Announce Partnership Enabling HSA/FSA Payments on Electromedical eCommerce Site

Retrieved on: 
Wednesday, January 25, 2023
HSA, Defence Bioengineering and Electromedical Laboratory, Health, Pain, FSA, Sika, Partnership, FDA, Patient, E-commerce, Chronic pain, Online shopping, Health insurance

SCOTTSDALE, Ariz., Jan. 25, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, and Sika Health, an HSA/FSA payment facilitator for eCommerce merchants, are pleased to announce a partnership enabling the direct acceptance of HSA/FSA payments on the Electromedical eCommerce website (electromedtech.com).

Key Points: 
  • SCOTTSDALE, Ariz., Jan. 25, 2023 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, and Sika Health, an HSA/FSA payment facilitator for eCommerce merchants, are pleased to announce a partnership enabling the direct acceptance of HSA/FSA payments on the Electromedical eCommerce website ( electromedtech.com ).
  • "This is a game-changer in terms of our ability to facilitate payments and tap into greater affordability without sacrificing margins," remarked Matthew Wolfson, CEO and Founder of Electromedical.
  • "Sika's payment technology is seamless and easy to use, and the Sika team has been exceptional to work with."
  • The partnership between Sika Health and Electromedical aims to close this gap and offer patients a seamless way to take full advantage of their benefits.

Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022

Retrieved on: 
Monday, December 5, 2022
Cloud, Stock dilution, Federal Food, Drug, and Cosmetic Act, Retirement, Negotiation, Pain, VNS, Sale, IDNA, Loss, Research, PNS, Q1, ALL, CES, Low-level laser therapy, FDA, Bioelectronics, Overalls, EMS, POD, Growth, University, Infinity, PEMF, Marketing, TENS, Renewable energy, Pharmaceutical industry, Medical imaging, Video game console, Risk management

SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.

Key Points: 
  • Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022
    SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ -- Electromedical Technologies, Inc. (OTC-QB: EMED) ("Electromedical" or the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.
  • Highlights for the three and nine months ended Sep 30, 2022
    Strong net sales during the quarter totaling approximately $280,000, beating both Q1 and Q2 2022 sales.
  • Net loss for the nine months ended Sep 30, 2022, of $2.64 million, a 60% improvement over net loss for the nine months ended Sep 30, 2021.
  • Approximately $900K in net financing used to expedite development of the new WellnessPro Infinity Flagship Device.